Immunome Doses First Patient in Phase 1 Trial of IM-3050 for Advanced Solid Tumours
Tuesday, July 21, 2026
Immunome has dosed the first patient in a Phase 1, first-in-human clinical trial evaluating IM-3050, an investigational fibroblast activation protein (FAP)-targeted radioligand therapy, in patients with FAP-expressing advanced solid tumours.
The open-label, multicentre study is designed to assess the safety, tolerability, dosimetry, pharmacokinetics and preliminary anti-tumour activity of IM-3050. The dose-escalation stage will evaluate repeated increasing doses of the therapy to determine the maximum tolerated dose and the recommended dose for further clinical development. The expansion stage will further assess the treatment's safety and tolerability at the selected dose.
IM-3050 is an investigational lutetium-177-based radioligand therapy that targets fibroblast activation protein (FAP), a protein widely expressed on cancer-associated fibroblasts within the tumour microenvironment. FAP is found in approximately 75% of solid tumours, making it a potential target for radioligand-based treatment.
The therapy is designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The emitted beta radiation is intended to damage or destroy nearby tumour cells through a bystander effect, providing a targeted treatment approach for patients with advanced solid tumours.
Source: businesswire.com
